ThirdPartyVerified
Compound Guides/Tirzepatide

Tirzepatide

Dual GIP/GLP-1 Receptor Agonist

Updated September 2026
Regulatory notice

Tirzepatide is an FDA-approved prescription medication (Mounjaro for type 2 diabetes, Zepbound for weight management). Like semaglutide, it has extensive Phase III clinical trial data. The regulatory landscape for compounded versions follows similar dynamics to semaglutide. This guide covers the science and lab testing — not dosing, prescribing, or sourcing.

Quick Facts

Class
Dual GIP/GLP-1 Receptor Agonist
Sequence Length
39 amino acids (modified); ~4,813.5 Da
Based On
Native GIP sequence (with GLP-1 cross-reactivity engineered in)
Developer
Eli Lilly
FDA Approvals
Mounjaro (May 2022, T2D), Zepbound (Nov 2023, weight management), Zepbound for obstructive sleep apnea (Dec 2024), Mounjaro for children 10+ with T2D (Dec 2025), Mounjaro for cardiovascular risk reduction (Aug 2026)
Key Distinction
First dual incretin agonist — activates both GIP and GLP-1 receptors
Human Clinical Data
Extensive — SURPASS (T2D) and SURMOUNT (obesity) trial programs
Dosing
Once-weekly subcutaneous injection (half-life ~5 days, ~5–6 days in obesity)

What Is Tirzepatide

Tirzepatide is a synthetic 39-amino-acid peptide developed by Eli Lilly that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. It is the first dual incretin receptor agonist approved by the FDA — a new class distinct from GLP-1-only drugs like semaglutide.

The peptide is based primarily on the native GIP sequence, with modifications that enable it to also activate the GLP-1 receptor: alpha-aminoisobutyric acid at positions 2 and 13, a C-terminal amide, and a C20 fatty diacid attached to the lysine at position 20 through a linker. That fatty acid extends its half-life to roughly five days, enabling once-weekly dosing. Its molecular weight is approximately 4,813.5 Da.

Why Dual Agonism Matters

Semaglutide activates one receptor (GLP-1R). Tirzepatide activates two (GIP-R and GLP-1R). In head-to-head clinical trials, this dual mechanism produced greater weight loss and blood sugar reduction than GLP-1 agonism alone:

GLP-1 Pathway

Reduces appetite via brain receptors, slows gastric emptying, stimulates glucose-dependent insulin release, suppresses glucagon. This is the same pathway semaglutide uses.

GIP Pathway (additional)

GIP receptor agonism appears to contribute additional weight loss and metabolic effects beyond what GLP-1 alone achieves. The proposed mechanisms — effects on adipose tissue handling of glucose and lipids, and a dampening of GLP-1-driven nausea — come largely from animal studies, and the field is genuinely unsettled: GIP receptorantagonists also produce weight loss in humans.

Clinical Evidence

SURPASS trials (Type 2 Diabetes). In the SURPASS-1 monotherapy trial, tirzepatide 5, 10, and 15 mg lowered HbA1c by 1.87–2.07% from baseline versus +0.04% on placebo at 40 weeks (1.69–1.75% counting everyone randomised, regardless of whether they stayed on treatment). The open-label head-to-head SURPASS-2 trial showed tirzepatide 15 mg produced a 2.3% HbA1c reduction and about 11 kg (25 lb) of weight loss, both superior to semaglutide at 1 mg weekly — which was the highest approved Ozempic dose at the time, though 2 mg is approved now.
SURMOUNT-1 (Obesity). In 2,539 adults without diabetes who had a BMI of 30 or more, or 27 or more with a weight-related complication, tirzepatide produced mean body weight reductions of 15.0% at 5 mg, 19.5% at 10 mg and 20.9% at 15 mg over 72 weeks, versus 3.1% on placebo. Those are the figures counting everyone randomised, which is what the FDA label reports; among participants who stayed on treatment the reductions reached 16.0%, 21.4% and 22.5%. This data supported the FDA approval of Zepbound in November 2023.
SURPASS-2 head-to-head vs semaglutide. Tirzepatide outperformed semaglutide 1 mg on both glycemic control and weight loss, supporting the hypothesis that the GIP component provides additive efficacy beyond GLP-1 agonism alone. For a comparison at weight-management doses, the later SURMOUNT-5 trial put tirzepatide at 20.2% weight loss against semaglutide 2.4 mg at 13.7% over 72 weeks.

Compounding Considerations

Like semaglutide, tirzepatide faces an evolving regulatory landscape regarding compounded versions:

  • Tirzepatide came off the FDA shortage list in late 2024, and enforcement discretion for compounders ended in February and March 2025, so compounding it no longer has a shortage-based legal basis. On 30 April 2026 FDA proposed excluding tirzepatide, semaglutide and liraglutide from the 503B outsourcing facility bulk drug substance list; that proposal is still pending a final determination.
  • Compounded tirzepatide faces the same quality concerns as compounded semaglutide. FDA had received more than 730 adverse event reports tied to compounded tirzepatide as of May 2026, and notes that the salt forms some compounders use have no lawful basis. A 2026 analysis published in Expert Opinion on Drug Safety reported a tirzepatide–B12 adduct impurity, absent from the approved product, in mass-compounded tirzepatide/B12 products — though its authors are all Eli Lilly employees, so read it with that interest in mind.
  • As a dual agonist with a more complex structure than semaglutide, synthesis of research-grade tirzepatide at high purity is more challenging.

The regulatory situation continues to change. Check current FDA guidance for the latest status.

Limitations

  • Gastrointestinal side effects are common. Nausea, vomiting, diarrhea, abdominal pain, and constipation affect a significant proportion of patients, particularly during dose escalation. In the pivotal trials, adverse events led 4–8% of participants to stop treatment, depending on dose and trial.
  • Long-term data beyond 72 weeks is limited. The SURMOUNT trials ran for 72 weeks. Effects and safety beyond that timeframe are still being studied.
  • Weight regain on discontinuation. In SURMOUNT-4, participants who switched to placebo after 36 weeks of treatment regained a mean 14% of body weight over the following year, while those who continued kept losing. Only 16.6% of the placebo group held on to most of their earlier loss, versus 89.5% of those who continued.
  • Compounded versions carry uncharacterized risk. The quality, purity, and potency of compounded tirzepatide are not guaranteed by the FDA approval of Mounjaro/Zepbound, which applies only to Eli Lilly's manufactured product.

Purity and Lab Testing

Mass Spectrometry

Identity confirmation via mass spec is critical. Tirzepatide is a 39-amino-acid peptide with a fatty acid modification. Mass spec distinguishes it from semaglutide (~4,114 Da) and other incretin analogs, which a purity figure alone cannot do.

HPLC Purity

At 39 amino acids with modifications, tirzepatide is a complex synthesis. High-quality product should test at 95% or above. The complexity of the molecule means synthesis impurities (truncated sequences, incomplete modifications) are more likely than with shorter peptides.

Dual Receptor Activity Verification

Standard analytical tests (HPLC, MS) confirm purity and identity but do not confirm biological activity at both GIP and GLP-1 receptors. Functional receptor assays are not part of standard third-party COA testing for research compounds.

For a complete guide to evaluating COAs, see How to Read a Peptide COA.

Summary

Tirzepatide is the first dual GIP/GLP-1 receptor agonist, approved as Mounjaro (T2D) and Zepbound (weight management). Head-to-head trials showed superiority over semaglutide on both glycemic control and weight loss. As with semaglutide, the quality question for compounded versions centers on third-party lab testing — particularly mass spectrometry to confirm identity and HPLC to verify purity of this complex 39-amino-acid peptide.